9.00am-9.15am : Registration, networking, tea and coffee
9.15am- 9.30am : Introduction to the Solentim team
9.30am-10.00am: Miriam Mendez-Tavio, Senior Scientist – Cell Line Development, GSK- ”Optimising Outgrowth of Lentiviral Vector Producing Stable Cell Lines after Single Cell Printing”
10.00am-10.30am: Aljona Kolmogorova, Process Development Scientist, Horizon Discovery- ”High Throughput Imaging for Identifying Clonal Populations in Edited Cell Lines”
10.30am – 10.45am: Coffee break
10.45am-11.30am: Paul Butler, Marta Rucka, Andrea Gough, Advanced Instruments- ”Latest Technology Developments from Solentim”
11.30am-12.30pm: Roundtable Discussion: Main Bottlenecks and Challenges in the CLD Workflow
12.30pm- 2.00pm: Lunch + Networking Session + Tour of Museum
2.00pm-2.30pm: Emma Morris, Business Development Field Application Scientist, Advanced Instruments- ”STUDIUS Interactive Demo”
2.30pm-3.00pm: Paul Butler, Marta Rucka, Andrea Gough, Neil Pomeroy, Advanced Instruments- ”Trends in CLD and the Vision for AI/Solentim’s solutions”
3.00pm -3.30pm: Chrysanthi Sitmalidou, Associate Scientist, Orchard Therapeutics- ”Implementation of the VIPS™ system into Orchard’s CLD workflow”
3.30pm-4.00pm: Coffee + Networking
4.00pm-4.30pm: Camilla Domeneghetti, Laboratory Manager, Advanced Instruments- ”Applications Lab Overview”
4.30pm-5.00pm: Kalpana Wood, Senior Manager-Cell Line Development, Abzena- ”Application of the Solentim Cell Metric® Instrument in Abzena’s Cell Line Development Process ”
5.00pm-5.30pm: Final Remarks and Close
Speaker: Miriam Mendez-Tavio, Senior Scientist – Cell Line Development, Cell & Gene Therapy Product Development, R&D Medicinal Science & Technology
Company: GSK Medicines Research Centre
Bio: Miriam is a Senior Scientist in the Cell & Gene Therapy CLD team at GSK. Before joining GSK in 2018, Miriam earned a MSc in Novel Therapies at Imperial College London.
Abstract: The CGT CLD team at GSK performed an evaluation study to assess if Solentim’s InstiGRO™ HEK supplement improved colony outgrowth of lentiviral vector producing stable cell lines after single cell printing, without affecting long term cell health and vector production.
Speaker: Aljona Kolmogorova, Process Development Scientist
Company: Horizon Discovery
Bio: Internationally trained PhD-level scientist (UK/USA/Australia); Multilingual (German/Russian/English) with talents inneuroscience, entrepreneurship, bio business and creative endeavours (e.g. dance).
Abstract: Horizon Discovery (a PerkinElmer company) is a contract research organisation focussing on cells, cell-based assays, screening and genetically modified cell lines. The Cell Line Engineering department uses CRISPR/Cas9 to create genetically modified cell lines for clients to further their research and development. Cell lines are transfected with gRNAs, and Cas9 to target the locus/gene of interest. The edited pools are then cultured at limiting dilutions to grow up clonal populations. Using the Solentim Cell Metric throughout our workflow enables us to monitor cell confluency and assess clonality at scale. After identifying clones, Next-Generation Sequencing is used to confirm the edit. Clones are expanded and shipped to the client. Using the Cell Metric in our workflow, increases the likelihood of picking clonal populations and helped us deliver hundreds of edited cell lines in 2021.
Speaker: Kalpana Wood, Senior Manager
Bio: Analyst experienced in assay development for characterization of antibodies and proteins from cell culture determining PQAs. Upstream cell culture in bioreactors of various sizes.
Abstract: Abzena has over 10 years’ experience in Cell Line Development completing approximately 100 projects, expressing new biological entities or biosimilar molecules including antibodies, antibody fragments, fusion proteins and other novel modalities. As defined by ICHQ5D and EMA/CHMP guidelines, it is critical for the development of a therapeutic protein that the cell substrate used for production consists of a monoclonal population. At Abzena, the Cell Metric Instrument has been validated and incorporated into our development platform as a key instrument to provide visual assurance of monoclonality. This methodology enables the selection of high quality clonal cell lines for generation of biotherapeutics for the clinic with improvements in timelines over the more traditional two-rounds of cloning by limited dilution which historically was required to achieve a high probability of monoclonality.
Speaker: Chrysanthi Sitmalidou, Associate Scientist
Bio: Experienced Scientist with a demonstrated history of industrial experience. Skilled in Cell Line Development, Viral vector upstream Process Development and Molecular & Cellular Biology. Strong research professional with a Master of Science – MSc focused on Molecular Medicine and Cancer Research from Brunel University London.
Abstract: Orchard Therapeutics is currently developing a CLD platform for the future programs, which is where VIPS system aligns as a tool for single cell isolation and assurance of monoclonality. We have started to explore the potentials of the instrument, so far by developing and optimisation of different parameters during single cell isolation for a full implementation of VIPS into our CLD workflow.